RE:RE:RE:RE:RE:RE:RE:RE:TRT POST FROM THE OTHER BOARD RE AGM THANKS TRTAs I think many would agree this is a very interesting time for RVX. What I find most interesting is that I think there must be a lot of risk reward analysis going on in at least a few pharmas. How competitive would the bidding be and what would be the cost to try and lock RVX up now vs the risk of REMACE failure? How competitive and what would the cost be to aquire RVX if Ken Dart gains control of RVX and takes it through succesful REMACE on his own (gotta think that would be a huge number). In a scenario where RVX was just a company that had science with great commercial potential but had no deep pocketed investor in the wings I think pharma might be inclined to try and make that company come begging however I think they know if Ken Dart gains control it will be them who will ultimately be doing the begging in the form of bidding, in the event RVX-208 is a success. The actual cost of the REMACE trial is small risk relative to huge potential reward to either a pharma or Ken Dart and in some ways I think the tension created by this puts RVX in a good position to get fair value treatment as neither pharma nor Ken Dart would likely want to lose opportunity in RVX to the other "on the cheap". Personally, with a CVR based deal I can see where pre REMACE financial risk can be kept down and a pharma, Ken Dart and other existing shareholders all win in the event of a commercially successful RVX-208. IMO it would require a very large backend cap on shareholder payout.